

Guido Marcucci

List of Publications by Citations

Source: <https://exaly.com/author-pdf/11061595/guido-marcucci-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186
papers

23,255
citations

78
h-index

152
g-index

189
ext. papers

25,917
ext. citations

6.8
avg, IF

6.12
L-index

#	Paper	IF	Citations
186	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 15805-10	11.5	1385
185	Targeting microRNAs in cancer: rationale, strategies and challenges. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 775-89	64.1	1143
184	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017 , 377, 454-464	59.2	1067
183	Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. <i>New England Journal of Medicine</i> , 2014 , 371, 1005-15	59.2	885
182	MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. <i>Blood</i> , 2009 , 113, 6411-8	2.2	655
181	IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2348-55	2.2	599
180	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. <i>Blood</i> , 2008 , 111, 3183-9	2.2	536
179	Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3904-11	2.2	534
178	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/mA/MYC/CEBPA Signaling. <i>Cell</i> , 2018 , 172, 90-105. 533	53.3	479
177	Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. <i>Blood</i> , 2007 , 109, 431-48	2.2	452
176	Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. <i>Journal of Clinical Oncology</i> , 2011 , 29, 475-86	2.2	430
175	miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. <i>Cell</i> , 2010 , 140, 652-65	56.2	427
174	Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. <i>Cancer Discovery</i> , 2014 , 4, 362-75	24.4	420
173	Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 7473-8	11.5	399
172	The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. <i>Cancer Cell</i> , 2005 , 8, 355-68	24.3	391
171	MicroRNA expression in cytogenetically normal acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2008 , 358, 1919-28	59.2	386
170	MicroRNA fingerprints during human megakaryocytopoiesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 5078-83	11.5	386

169	MicroRNA 29b functions in acute myeloid leukemia. <i>Blood</i> , 2009 , 114, 5331-41	2.2	379
168	A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. <i>Blood</i> , 2005 , 105, 959-67	2.2	335
167	Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4515-23	2.2	310
166	Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3884-91	2.2	287
165	An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2008 , 112, 4193-201	2.2	281
164	Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5705-17	2.2	272
163	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2007 , 117, 2408-21	15.9	270
162	Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 596-604	2.2	268
161	TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1373-81	2.2	266
160	Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5078-87	2.2	266
159	High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. <i>Journal of Clinical Oncology</i> , 2017 , 35, 394-401	2.2	227
158	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. <i>Blood</i> , 2008 , 111, 1552-9	2.2	221
157	The prognostic and functional role of microRNAs in acute myeloid leukemia. <i>Blood</i> , 2011 , 117, 1121-9	2.2	218
156	Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. <i>Cancer Cell</i> , 2010 , 17, 333-47	24.3	218
155	ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. <i>Blood</i> , 2011 , 118, 6920-9	2.2	216
154	Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 742-50	2.2	215
153	BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. <i>Blood</i> , 2003 , 102, 1613-8	2.2	202
152	WilmsPtumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4595-602	2.2	200

151	Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9234-42	2.2	199
150	RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3109-18	2.2	195
149	NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9 Suppl 5, S1-32; quiz S33	7.3	195
148	NCCN Clinical Practice Guidelines Acute myeloid leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 984-1021	7.3	194
147	Expression and prognostic impact of lncRNAs in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 18679-84	11.5	181
146	FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010 , 116, 3622-6	2.2	179
145	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019 , 133, 1548-1559	2.2	178
144	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4144-57	15.9	170
143	High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3337-43	2.2	165
142	Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 1765-73	2.2	161
141	High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. <i>Blood</i> , 2008 , 111, 5371-9	2.2	159
140	A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. <i>Blood</i> , 2006 , 107, 2507-16	2.2	159
139	Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 5257-64	2.2	155
138	Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. <i>Clinical Cancer Research</i> , 2013 , 19, 2355-67	12.9	146
137	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016 , 48, 1481-1489	36.3	145
136	Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. <i>Blood</i> , 2003 , 102, 652-8	2.2	144
135	Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2086-93	2.2	141
134	Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3198-204	2.2	135

133	Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3404-11	2.2	133
132	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016 , 7, 13331	17.4	128
131	Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. <i>Blood</i> , 2012 , 119, 2314-24	2.2	128
130	Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia. <i>Cancer Research</i> , 2008 , 68, 3142-51	10.1	126
129	Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. <i>Blood</i> , 2013 , 121, 499-509	2.2	125
128	Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. <i>Blood</i> , 2008 , 111, 2364-73	2.2	124
127	Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. <i>Cancer Research</i> , 2005 , 65, 1277-84	10.1	122
126	Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. <i>Journal of Clinical Oncology</i> , 2014 , 32, 548-56	2.2	119
125	Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 6025-31	2.2	119
124	Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. <i>Cancer Cell</i> , 2012 , 22, 645-55	24.3	115
123	Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. <i>Blood</i> , 2013 , 122, 3034-44	2.2	114
122	Modulation of DNA methylation by a sesquiterpene lactone parthenolide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009 , 329, 505-14	4.7	114
121	Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1172-81	2.2	112
120	Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 597-602	2.9	109
119	Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. <i>Blood</i> , 2006 , 108, 1677-83	2.2	108
118	The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. <i>Blood</i> , 2005 , 106, 345-52	2.2	107
117	BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Blood</i> , 2010 , 116, 5660-9	2.2	99
116	RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. <i>Blood</i> , 2012 , 119, 5229-38	2.2	93

115	Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. <i>Blood</i> , 2013 , 122, 1923-34	2.2	90
114	Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2410-8	2.2	89
113	Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review. <i>British Journal of Haematology</i> , 2007 , 137, 387-400	4.5	88
112	Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. <i>Blood</i> , 2011 , 117, 5941-52	2.2	87
111	Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2482-92	2.2	86
110	Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. <i>Blood</i> , 2007 , 109, 5164-7	2.2	85
109	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015 , 125, 680-6	2.2	84
108	Dose escalation of lenalidomide in relapsed or refractory acute leukemias. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4919-25	2.2	73
107	Epigenetics in acute myeloid leukemia. <i>Seminars in Oncology</i> , 2008 , 35, 378-87	5.5	69
106	Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2008 , 20, 711-8	4.2	68
105	Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 321, 953-60	4.7	67
104	Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 2466-74	2.2	64
103	Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. <i>Nucleic Acids Research</i> , 2007 , 35, e31	20.1	64
102	Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricyclo[1.6.0]nonane] is mediated by reversible MDR1 induction in human cancer cell lines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 314, 467-75	4.7	60
101	Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv274	9.7	59
100	miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2012 , 120, 249-58	2.2	58
99	Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 136-47	2.2	58
98	Potential of microRNAs for cancer diagnostics, prognostication and therapy. <i>Current Opinion in Oncology</i> , 2012 , 24, 655-9	4.2	58

97	Lenalidomide-mediated enhanced translation of C/EBP β -p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. <i>Blood</i> , 2013 , 121, 159-69	2.2	53
96	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020 , 135, 371-380	2.2	53
95	Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. <i>Cancer</i> , 2011 , 117, 4696-706	6.4	52
94	Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. <i>Investigative Ophthalmology and Visual Science</i> , 2003 , 44, 2390-8		51
93	Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. <i>Blood</i> , 2011 , 118, 4188-98	2.2	48
92	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 16-27	7.3	46
91	Acute myeloid leukemia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 280-317	7.3	45
90	Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. <i>Oncogene</i> , 1999 , 18, 3159-65	9.2	45
89	Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons. <i>Analytical Chemistry</i> , 2013 , 85, 11265-74	7.8	43
88	Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 21	22.4	42
87	SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. <i>Journal of Clinical Investigation</i> , 2014 , 124, 1512-24	15.9	42
86	Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. <i>Blood</i> , 2014 , 124, 1127-35	2.2	41
85	Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. <i>Blood</i> , 2014 , 123, 2412-5	2.2	40
84	Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia. <i>Oncotarget</i> , 2016 , 7, 59273-59286	3.9	40
83	Myeloid cell-targeted miR-146a mimic inhibits NF- κ B-driven inflammation and leukemia progression in vivo. <i>Blood</i> , 2020 , 135, 167-180	2.2	40
82	Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. <i>Blood</i> , 2008 , 111, 816-28	2.2	39
81	GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. <i>Leukemia</i> , 2014 , 28, 1252-1258	10.7	38
80	Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. <i>British Journal of Haematology</i> , 2013 , 161, 406-10	4.5	38

79	Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. <i>Blood</i> , 2015 , 125, 2689-92	2.2	37
78	MicroRNA expression in acute myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , 2009 , 4, 83-8	4.4	36
77	A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. <i>Blood</i> , 2010 , 115, 2462-72	2.2	36
76	Molecular signatures in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2009 , 16, 64-9	3.3	35
75	inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFβ-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. <i>Blood</i> , 2013 , 121, 385-91	2.2	34
74	Molecular prognostic factors in cytogenetically normal acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2012 , 5, 547-58	2.8	28
73	Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia. <i>Current Opinion in Hematology</i> , 2015 , 22, 85-91	3.3	27
72	Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2084-2092	4.3	27
71	Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E4641-E4647	11.5	25
70	Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. <i>Blood</i> , 2013 , 122, 3778-83	2.2	25
69	Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 6668-73	11.5	23
68	Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity. <i>Molecular Pharmaceutics</i> , 2012 , 9, 1638-44	5.6	22
67	Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1304-8	1.9	21
66	MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias. <i>Best Practice and Research in Clinical Haematology</i> , 2009 , 22, 239-48	4.2	21
65	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020 , 4, 696-705	7.8	21
64	Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. <i>Leukemia</i> , 2014 , 28, 1754-1758	10.7	20
63	Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). <i>Blood Advances</i> , 2018 , 2, 3608-3617	7.8	20
62	Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. <i>Haematologica</i> , 2011 , 96, 1488-95	6.6	19

61	Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. <i>Leukemia Research</i> , 2017 , 59, 124-135	2.7	18
60	Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?. <i>European Journal of Haematology</i> , 2003 , 71, 143-54	3.8	18
59	ROR1-targeted delivery of miR-29b induces cell cycle arrest and therapeutic benefit in vivo in a CLL mouse model. <i>Blood</i> , 2019 , 134, 432-444	2.2	17
58	The emerging story of acute lymphoblastic leukemia among the Latin American population - biological and clinical implications. <i>Blood Reviews</i> , 2019 , 33, 98-105	11.1	17
57	A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.. <i>Blood</i> , 2005 , 106, 407-407	2.2	17
56	Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on Antiproliferative and PP2A-Activating Functions. <i>Blood Cancer Discovery</i> , 2020 , 1, 48-67	7	16
55	Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway. <i>Science Signaling</i> , 2014 , 7, ra36	8.8	16
54	Histone H4 N-terminal acetylation in Kasumi-1 cells treated with depsipeptide determined by acetic acid-urea polyacrylamide gel electrophoresis, amino acid coded mass tagging, and mass spectrometry. <i>Journal of Proteome Research</i> , 2007 , 6, 81-8	5.6	16
53	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021 , 35, 2539-2551	10.7	15
52	In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. <i>AAPS Journal</i> , 2013 , 15, 242-9	3.7	14
51	A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application. <i>AAPS Journal</i> , 2010 , 12, 556-68	3.7	14
50	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 1193	7.1	13
49	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). <i>Cancer Medicine</i> , 2018 , 7, 4447-4455	4.8	13
48	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020 , 4, 4945-4954	7.8	13
47	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1084-1090	4.7	11
46	A novel regimen for relapsed/refractory adult acute myeloid leukemia using a partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. <i>Haematologica</i> , 2018 , 103, 982-987	6.6	11
45	Impact of molecular prognostic factors in cytogenetically normal acute myeloid leukemia at diagnosis and relapse. <i>Haematologica</i> , 2011 , 96, 640-3	6.6	11
44	Phase I study of AR-42 and decitabine in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1484-1492	1.9	9

43	PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data. <i>Bioinformatics</i> , 2014 , 30, 3567-74	7.2	9
42	Enrichment-based DNA methylation analysis using next-generation sequencing: sample exclusion, estimating changes in global methylation, and the contribution of replicate lanes. <i>BMC Genomics</i> , 2012 , 13 Suppl 8, S6	4.5	9
41	New approaches in acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 29-41	4.2	7
40	Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance. <i>Nature Communications</i> , 2021 , 12, 6154	17.4	7
39	Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 580-597	2	7
38	Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). <i>Blood Advances</i> , 2019 , 3, 1714-1721	7.8	6
37	A 75-year-old woman with thoracic spinal cord compression and chloroma (granulocytic sarcoma). <i>Seminars in Oncology</i> , 2012 , 39, e37-46	5.5	5
36	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021 , 5, 2481-2489	7.8	5
35	Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 527-34	7.3	4
34	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016 , 128, 1166-1166	2.2	4
33	Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia. <i>Leukemia</i> , 2021 , 35, 2285-2298	10.7	4
32	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e400-e405	2	3
31	Targeted Delivery of miRNA Antagonists to Myeloid Cells In Vitro and In Vivo. <i>Methods in Molecular Biology</i> , 2019 , 1974, 141-150	1.4	3
30	FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34+ Progenitors Through Inhibition of Jak2 V617F- and PI-3K-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration. <i>Blood</i> , 2011 , 118, 2494-2494	2.2	3
29	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). <i>Blood Advances</i> , 2021 , 5, 2775-2787	7.8	3
28	Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 122	22.4	3
27	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1425-1432	4.7	2
26	Elucidation of the Molecular Mechanisms by Which Inflammatory and Anti-Inflammatory Monokines Regulate Interferon (IFN)- β Production. <i>Blood</i> , 2004 , 104, 111-111	2.2	2

25	MiRNA-29b Targets MCL-1 and Is Down-Regulated in Chemotherapy-Resistant Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2007 , 110, 717-717	2.2	2
24	Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts). <i>Blood</i> , 2011 , 118, 414-414	2.2	2
23	Epigenetic priming: the target?. <i>Blood</i> , 2011 , 118, 1430-1	2.2	1
22	Incidence of Extramedullary Relapse of Acute Myeloid Leukemia Following Transplantation with Busulfan-Based Conditioning Regimens.. <i>Blood</i> , 2004 , 104, 5123-5123	2.2	1
21	Dual Epigenetic Control of CCAAT/Enhancer Binding Protein β (C/EBP β) Expression in Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 2116-2116	2.2	1
20	Prognostic Significance of Karyotype in Octogenarian Patients (Pts) with Acute Myeloid Leukemia (AML) An International Study. <i>Blood</i> , 2011 , 118, 2521-2521	2.2	1
19	Impact of DNMT3A mutations on Clinical Response to the Hypomethylating Agent Decitabine in Older Patients (pts) with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011 , 118, 944-944	2.2	1
18	Evidence of MicroRNA-29b and Sp1/NFB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.. <i>Blood</i> , 2009 , 114, 938-938	2.2	0
17	Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the gene. <i>Haematologica</i> , 2021 , 106, 2527-2532	6.6	0
16	MicroRNA networks in FLT3-ITD acute myeloid leukemia.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2112482119	11.5	0
15	Identification of medium-sized copy number alterations in whole-genome sequencing. <i>Cancer Informatics</i> , 2014 , 13, 105-11	2.4	
14	Genetics and Classification of Acute Myeloid Leukemia 2015 , 1-25		
13	ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.. <i>Blood</i> , 2005 , 106, 1992-1992	2.2	
12	BCR/ABL Post-Translationally Enhances hnRNP E2 Expression and Translation-Inhibitory Function through the Activation of ERK1/2 Mitogen-Activated Protein Kinases.. <i>Blood</i> , 2005 , 106, 4376-4376	2.2	
11	Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD).. <i>Blood</i> , 2006 , 108, 4578-4578	2.2	
10	Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF-kB in AML1/ETO-Positive Cells.. <i>Blood</i> , 2006 , 108, 4211-4211	2.2	
9	Imatinib Mesylate-Induced Complete Cytogenetic Response in Acute Myeloid Leukemia with t(5;12)(q33;p13).. <i>Blood</i> , 2006 , 108, 4414-4414	2.2	
8	Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant <i>Aglaia Foveolata</i> inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011 , 118, 2616-2616	2.2	

- 7 Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,. *Blood*, **2011**, 118, 3454-3454 2.2
- 6 MLL-PTD Causes Hypomorph Condition of CBF Complex (RUNX1/CBF β) and Predisposes the Abnormal Hematopoietic Stem and Progenitor Cells (HSPCs) to Clonal Expansion. *Blood*, **2011**, 118, 2801-2801 2.2
- 5 Cytogenetic, Molecular and Clinical Features Associated with Rare CBFB-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16). *Blood*, **2011**, 118, 2514-2514 2.2
- 4 Combined Pharmacologic Inhibition of Bcl-Xl/Bcl-2 and mTORC1/2 Survival Signals Trigger Apoptosis in BCR-ABL1+in Vitro Models of Blast Crisis Chronic Myelogenous Leukemia (CML-BC), and Primary CD34+/CD38^{int} Stem and CD34+ progenitor Cells From CML-BC Patients. *Blood*, **2011**, 118, 3758-3758 2.2
- 3 Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity,. *Blood*, **2011**, 118, 3758-3758 2.2
- 2 Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.. *Blood*, **2011**, 118, 1791-1791 2.2
- 1 MiR-3151, a Novel MicroRNA Embedded in BAALC, Is Only Weakly Co-Expressed with Its Host Gene and Independently Impacts on the Clinical Outcome of Older Patients (Pts) with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). *Blood*, **2011**, 118, 1462-1462 2.2